Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Co
15 Octubre 2009 - 7:00AM
PR Newswire (US)
SAN DIEGO, Oct. 15 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc.
(OTC Bulletin Board: AEMD) disclosed today that clinical data
resulting from the treatment of Hepatitis-C (HCV) infected patients
with the Aethlon Hemopurifier® will be presented at the 42nd Annual
Meeting & Scientific Exposition of the American Society of
Nephrology (ASN). Dr. Vijay Kher, principal investigator of the
Hemopurifier® studies and Director of Nephrology at the Fortis
Hospital in New Delhi, India will present and discuss Hemopurifier®
treatment results from 10am-12pm pacific time on October 30th,
2009. The event is being held at The San Diego Convention Center in
San Diego, California. (Logo:
http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b) "We are
honored that Dr. Kher has been invited to travel from India to
present our clinical data at the largest annual gathering of
Nephrologists," stated Aethlon Chairman and CEO, Jim Joyce. The
Aethlon Hemopurifier® is the first-in-class medical device able to
selectively remove viruses and immunosuppressive proteins from the
bloodstream. In HCV care, the device targets to improve patient
cure rates as an adjunct to accelerate and enhance the performance
of current and future iterations of standard of care drug therapy.
About ASN More than 11,000 physicians and scientists, all committed
to preventing kidney disease and making life better for patients,
work together as members of the American Society of Nephrology
(ASN). Whether providing expert care to patients, performing
cutting-edge medical research, or training the next generation of
kidney experts, these nephrologists change lives. Through advocacy,
ASN informs policymakers about issues of importance to kidney
doctors and their patients. ASN also funds research, convenes
world-renowned meetings and generates educational tools that enable
nephrologists to be most effective. Building on a 40-year history,
ASN brings rigor, integrity, and ingenuity to all its work. Visit
http://www.asn-online.org/ for additional detail. About Aethlon
Medical Aethlon Medical creates diagnostic and therapeutic device
solutions for infectious disease and cancer. Our Hemopurifier®
represents the first-in-class medical device to selectively adsorb
viruses and immunosuppressive toxins from the bloodstream. The
Hemopurifier® seeks to improve Hepatitis-C treatment outcomes and
serves as a broad-spectrum treatment countermeasure against
bioterror and pandemic threats. Additional information regarding
Aethlon Medical can be accessed online at
http://www.aethlonmedical.com/. Certain of the statements herein
may be forward-looking and involve risks and uncertainties. Such
forward-looking statements involve assumptions, known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such potential risks and uncertainties include, without
limitation, the capability of the Hemopurifier® to reduce viral
loads and other disease conditions, the Company's ability to raise
capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of
its products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product
liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the
Company's Securities and Exchange Commission filings. Contacts:
RedChip Companies, Inc. Jon Cunningham 1-800-733-2447, Ext. 107 Jim
Joyce Chairman, CEO 858.459.7800 x301 Jim Frakes Senior VP Finance
858.459.7800 x300
http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b
http://photoarchive.ap.org/ DATASOURCE: Aethlon Medical, Inc.
CONTACT: Jon Cunningham of RedChip Companies, Inc., 1-800-733-2447,
ext. 107, , for Aethlon Medical, Inc.; Jim Joyce, Chairman, CEO,
+1-858-459-7800 ext. 301, , or Jim Frakes, Senior VP Finance,
+1-858-459-7800 ext. 300, , both of Aethlon Medical, Inc. Web Site:
http://www.aethlonmedical.com/
Copyright